Financial Performance Overview
Sai Parenterals Limited reported exceptional financial results for FY 2025-26 with consolidated revenue reaching ₹3,809.98 million, representing a 134% increase from ₹1,631.06 million in FY25. Despite the substantial revenue growth, profitability metrics showed pressure with Profit Before Tax declining 40% to ₹119.28 million and PAT Margin contracting to 3.77% from 8.88% in the previous year. The company completed its IPO in March 2026, raising ₹285 crore through primary fundraising, which significantly strengthened the balance sheet with cash and cash equivalents surging to ₹4,169.66 million from ₹20.86 million.
Strategic Expansion and Acquisitions
The company's transformational growth was primarily driven by the acquisition of controlling interest in Noumed Pharmaceuticals Pty Ltd on April 1, 2025, which added ₹1,246.27 million in goodwill and significantly expanded global operations. This acquisition was complemented by strategic initiatives including a ₹1,300 crore OTC medicines supply agreement for 7.5 years in Australia, planned Adelaide facility with AUD 53 million investment (₹311 crore), and proposed 60% equity acquisition in Prathyak Laboratories Private Limited for ₹15 crore instead of greenfield R&D facility. Capital work-in-progress increased substantially to ₹2,122.05 million from ₹5.00 million, indicating major expansion projects underway.
Operational and Capacity Metrics
The Group maintains ~1,160 million units annual manufacturing capacity across 5 facilities with 599+ products across 30+ therapeutic areas, supplying to 50+ partners across 4 continents. Property, plant and equipment grew to ₹1,021.23 million (net block ₹616.08 million) while intangible assets increased significantly to ₹479.14 million primarily due to acquisition of licenses valued at ₹473.64 million. Total borrowings increased to ₹3,194.85 million from ₹939.54 million, primarily funding expansion and the Noumed acquisition.
Corporate Governance and Regulatory Compliance
The company submitted its 25th Annual Report for FY 2025-26 to BSE and NSE in compliance with SEBI LODR Regulation 34, with AGM scheduled for September 10, 2026. The Board composition includes 6 directors (3 independent, 2 executive, 1 non-executive non-independent) with comprehensive suite of 17+ governance policies. Key AGM resolutions include reappointment of Mr. Anil Kumar Karusala as Managing Director (₹2.05 crore p.a.), reappointment of Mrs. Vijitha Gorrepati as Whole-time Director (₹1.83 crore p.a.), ratification of ESOP Scheme 2025, and approval of material related party transactions with Noumed Pharmaceuticals.
Capital Structure and Shareholding
Paid-up capital stands at ₹22.0896 crore (4,417,923 equity shares) with promoters holding 51.16% and public shareholders 48.84%. The ESOP pool allocates 500,000 equity shares for employee stock option plan. IPO proceeds utilization saw ₹838.34 million redirected from capacity expansion to acquisition of Saicriti Pharma Private Limited and ₹180.23 million redirected from R&D centre to Prathyak Laboratories acquisition.
Forward Outlook and Expansion Plans
The company targets European GMP upgrades completion by January 2027 and Adelaide facility commercial production in Q1 CY2027. Planned launch of 12 new products annually in Australian market with R&D focus on complex generics, sterile injectables, and regulated-market products. The strategic expansion positions Sai Parenterals for continued growth in global pharmaceutical markets through both organic and inorganic initiatives.